Cargando…

Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

SIMPLE SUMMARY: About 20% of patients with cancer who participate in a phase I clinical trial discontinue the trial early. Early trial discontinuation is undesirable both for the wellbeing of the patient as well as for the trial efficiency and the development of new anticancer drugs. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Douma, Joeri A. J., Buffart, Laurien M., Sedhom, Ramy, Labots, Mariette, Menke-van der Houven van Oordt, Willemien C., Skardhamar, Mikkjal, De Felice, Anthony, Lee, Esther, Dharmaraj, Divya, Azad, Nilofer S., Carducci, Michael A., Verheul, Henk M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151105/ https://www.ncbi.nlm.nih.gov/pubmed/34064995 http://dx.doi.org/10.3390/cancers13102304

Ejemplares similares

Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials
por: Douma, Joeri A. J., et al.
Publicado: (2020)

Feasibility, validity and reliability of objective smartphone measurements of physical activity and fitness in patients with cancer
por: Douma, Joeri A. J., et al.
Publicado: (2018)

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

Early (18)F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
por: van Helden, Erik J., et al.
Publicado: (2016)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2016)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

Optimal imaging time points considering accuracy and precision of Patlak linearization for (89)Zr-immuno-PET: a simulation study
por: Wijngaarden, Jessica E., et al.
Publicado: (2022)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

Explainable artificial intelligence (XAI) in radiology and nuclear medicine: a literature review
por: de Vries, Bart M., et al.
Publicado: (2023)

The Mkk(3/6)-p38–Signaling Cascade Alters the Subcellular Distribution of Hnrnp A1 and Modulates Alternative Splicing Regulation
por: van der Houven van Oordt, Willemien, et al.
Publicado: (2000)

Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
por: Sedhom, Ramy, et al.
Publicado: (2020)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
por: Werter, Inge M., et al.
Publicado: (2022)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

[(18)F]FES uptake in the pituitary gland and white matter of the brain
por: Iqbal, R., et al.
Publicado: (2021)

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
por: Mammatas, L. H., et al.
Publicado: (2020)

Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2019)

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
por: van Helden, E. J., et al.
Publicado: (2018)

Diagnostic Performance of [(18)F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
por: Iqbal, Ramsha, et al.
Publicado: (2021)

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
por: Jager, Agnes, et al.
Publicado: (2020)

Mini-review of kidney disease following hematopoietic stem cell transplant 
por: Sedhom, Ramy, et al.
Publicado: (2018)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

Development and use of a flexible data harmonization platform to facilitate the harmonization of individual patient data for meta-analyses
por: Kalter, Joeri, et al.
Publicado: (2019)

Gender differences in clinical registration trials: is there a real problem?
por: Labots, Geert, et al.
Publicado: (2018)

Design of the Resistance and Endurance exercise After ChemoTherapy (REACT) study: A randomized controlled trial to evaluate the effectiveness and cost-effectiveness of exercise interventions after chemotherapy on physical fitness and fatigue
por: Kampshoff, Caroline S, et al.
Publicado: (2010)

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting
por: Bos, Manouk K., et al.
Publicado: (2023)

Validation of simplified uptake measures against dynamic Patlak K(i) for quantification of lesional (89)Zr-Immuno-PET antibody uptake
por: Wijngaarden, Jessica E., et al.
Publicado: (2023)

Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials
por: Buffart, Laurien M, et al.
Publicado: (2012)

(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018)

Visual and quantitative evaluation of [(18)F]FES and [(18)F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
por: Mammatas, Lemonitsa H., et al.
Publicado: (2020)

Discussing Goals of Care With Families Using the Four Steps
por: Sedhom, Ramy, et al.
Publicado: (2016)

Teaching Our Doctors to Care for the Elderly: A Geriatrics Needs Assessment Targeting Internal Medicine Residents
por: Sedhom, Ramy, et al.
Publicado: (2017)

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse
por: Bensch, Frederike, et al.
Publicado: (2018)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body (18)F-Fluorodeoxyglucose and (89)Zr-Rituximab PET Scans
por: de Vries, Bart M., et al.
Publicado: (2022)

Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial
por: Schuit, Anouk S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nh9v7ibu21kup1r41pp3ipknno